Engene Holdings Inc. (ENGNW)
NASDAQ (CM) NASDAQ (CM) Primary Summary
Engene Holdings Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| BO Brian Oliveira Clear Street Group Inc. | 300 | $213 | $75 | -$138 | -64.79% |
Engene Holdings Inc. (ENGNW) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Engene Holdings Inc. ever had a stock split?
Engene Holdings Inc. Profile
| Biotechnology Industry | Healthcare Sector | Ronald H. W. Cooper CEO | NASDAQ (CM) Exchange | 29286M113 CUSIP |
| CA Country | 56 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
enGene Holdings Inc. stands as a vanguard in the sector of biotechnological advancements, focusing its efforts through its subsidiary, enGene, Inc. This clinical-stage biotechnology company has dedicated itself to the development of genetic medicines, emphasizing the targeted delivery of therapeutics to mucosal tissues alongside other vital organs. Incorporated in 2023, enGene Holdings Inc. anchors its operations in Saint-Laurent, Canada, symbolizing a blend of innovative research and steadfast dedication towards addressing some of the most challenging medical conditions faced today.
Products and Services
EG-70 (detalimogene voraplasmid)
This product represents enGene Holdings Inc.'s forefront in its array of offerings, manifesting as a cutting-edge, non-viral immunotherapy. Targeted towards patients suffering from non-muscle invasive bladder cancer, particularly those with carcinoma-in-situ (Cis) who have not responded to the traditional Bacillus Calmette-Guérin treatment, EG-70 stands as a testament to the company's innovative strides in genetic medicine. This lead product candidate epitomizes the company's ambition to revolutionize the treatment landscape for a niche yet significantly impacted patient demographic.
